Mostrar el registro sencillo del ítem
dc.contributor.author
Bruna, Flavia Alejandra
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Plaza, Anita
dc.contributor.author
Arango, Martha
dc.contributor.author
Espinoza, Iris
dc.contributor.author
Conget, Paulette
dc.date.available
2019-11-11T19:27:26Z
dc.date.issued
2018-05
dc.identifier.citation
Bruna, Flavia Alejandra; Plaza, Anita; Arango, Martha; Espinoza, Iris; Conget, Paulette; Systemically administered allogeneic mesenchymal stem cells do not aggravate the progression of precancerous lesions: A new biosafety insight; BioMed Central; Stem Cell Research and Therapy; 9; 1; 5-2018; 1-10
dc.identifier.issn
1757-6512
dc.identifier.uri
http://hdl.handle.net/11336/88536
dc.description.abstract
Background: Mesenchymal stem cells (MSCs) are a heterogeneous subset of stromal cells currently tested for multiple therapeutic purposes. Their potential to home into tumors, to secrete trophic/vasculogenic factors, and to suppress immune response raises questions regarding their biosafety. Our aim was to evaluate whether systemically administered allogeneic MSCs modify the natural progression of precancerous lesions and whether their putative effect depends on cancer stage and/or cell dose. Methods: Oral squamous cell carcinoma (OSCC) was induced in Syrian golden hamsters by topical application of 7,12-dimethylbenz[a]anthracene in one buccal pouch. At hyperplasia, dysplasia, or papilloma stage, animals received intracardially the vehicle or 0.7 × 10 6 , 7 × 10 6 , or 21 × 10 6 allogeneic bone marrow-derived MSCs/kg. OSCC progression was assessed according to the presence of erythroplakia and leukoplakia, extent of inflammation and vascularization, and appearance, volume, and staging of tumors. Also, the homing of donor cells was studied. Results: Precancerous lesions progressed from hyperplasia to dysplasia in 2 weeks, from dysplasia to papilloma in 3 weeks, and from papilloma to carcinoma in 4 weeks. This time course was unmodified by the systemic administration of MSCs at hyperplasia or dysplasia stages. When MSCs were administered at papilloma stage, lesions did not progress to carcinoma stage. Tumors developed in hamsters receiving 0.7 × 10 6 or 7 × 10 6 MSCs/kg at hyperplasia stage were significantly smaller than those found in control animals (25 ± 4 or 23 ± 4 mm 3 versus 72 ± 19 mm 3 , p < 0.05). Similar results were obtained when 0.7 × 10 6 , 7 × 10 6 , or 21 × 10 6 MSCs/kg were administered at papilloma stage (44 ± 15, 28 ± 7, or 28 ± 5 mm 3 versus 104 ± 26 mm 3 , p < 0.05). For dysplasia stage, only the lower concentration of MSCs reached statistical significance (21 ± 9 mm 3 versus 94 ± 39 mm 3 , p < 0.05). Animals receiving 21 × 10 6 MSCs/kg at hyperplasia stage developed tumors larger than those found in animals that received the vehicle (147 ± 47 mm 3 versus 72 ± 19 mm 3 , p < 0.05). Donor cells were rarely found in precancerous lesions. Conclusions: Systemically administered allogeneic MSCs do not aggravate the progression of precancerous lesions. Moreover, they preclude cancer progression and tumor growth.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
BioMed Central
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
BIOSAFETY
dc.subject
CANCER PROGRESSION
dc.subject
MESENCHYMAL STEM CELLS
dc.subject
MULTIPOTENT STROMAL CELLS
dc.subject
ORAL SQUAMOUS CELL CARCINOMA
dc.subject
SYSTEMIC ADMINISTRATION
dc.subject.classification
Tecnologías que involucran la manipulación de células, tejidos, órganos o todo el organismo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Biotecnología de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Systemically administered allogeneic mesenchymal stem cells do not aggravate the progression of precancerous lesions: A new biosafety insight
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-10-21T20:08:20Z
dc.journal.volume
9
dc.journal.number
1
dc.journal.pagination
1-10
dc.journal.pais
Reino Unido
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Londres
dc.description.fil
Fil: Bruna, Flavia Alejandra. Universidad del Desarrollo; Chile. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
dc.description.fil
Fil: Plaza, Anita. Universidad del Desarrollo; Chile
dc.description.fil
Fil: Arango, Martha. Universidad del Desarrollo; Chile
dc.description.fil
Fil: Espinoza, Iris. Universidad de Chile; Chile
dc.description.fil
Fil: Conget, Paulette. Universidad del Desarrollo; Chile
dc.journal.title
Stem Cell Research and Therapy
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1186/s13287-018-0878-1
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-0878-1
Archivos asociados